Literature DB >> 6758119

Clinical relevance of antithrombin III.

R L Bick.   

Abstract

Many unrelated clinical conditions that are associated with significant decreases in antithrombin III have been summarized. In addition, prospects for future therapy with antithrombin III concentrates have been discussed. The clinical indications for antithrombin III determinations, including the reasons for performing the assay and those specific patient populations subjected to antithrombin III assays in this author's clinical practice, have been outlined. It is to be anticipated that with the new general availability of simple reliable antithrombin III assay systems using synthetic substrates that more and more populations will be adequately studied and clinical indications for the use of antithrombin III determinations and concentrates may become more firm or may change.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6758119     DOI: 10.1055/s-2007-1005058

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  7 in total

Review 1.  Streptokinase--the drug of choice for thrombolytic therapy.

Authors:  Adinarayana Kunamneni; Thaer Taleb Abed Abdelghani; Poluri Ellaiah
Journal:  J Thromb Thrombolysis       Date:  2007-02       Impact factor: 2.300

Review 2.  Disseminated intravascular coagulation: diagnosis and management.

Authors:  K L Saving
Journal:  Indian J Pediatr       Date:  1987 May-Jun       Impact factor: 1.967

3.  Use of antithrombin III in critical patients.

Authors:  J M Díaz-Cremades; R Lorenzo; M Sánchez; M J Moreno; M J Alsar; J M Bosch; L Fajardo; D González; D Guerrero
Journal:  Intensive Care Med       Date:  1994-11       Impact factor: 17.440

4.  Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor.

Authors:  I M Nilsson; H Ljungnér; L Tengborn
Journal:  Br Med J (Clin Res Ed)       Date:  1985-05-18

5.  Modulation of hemostatic balance with antithrombin III replacement therapy in a case of liver cirrhosis associated with recurrent venous thrombosis.

Authors:  F Carmassi; M Morale; F De Negri; M Carrai
Journal:  J Mol Med (Berl)       Date:  1995-02       Impact factor: 4.599

6.  The Streptokinase Therapy Complications and its Associated Risk Factors in Patients with Acute ST Elevation Myocardial Infarction.

Authors:  Naser Aslanabadi; Naser Safaie; Fereshteh Talebi; Samaneh Dousti; Taher Entezari-Maleki
Journal:  Iran J Pharm Res       Date:  2018       Impact factor: 1.696

Review 7.  Site-specific pharmaco-laser therapy: A novel treatment modality for refractory port wine stains.

Authors:  M Ingmar van Raath; Jojanneke E van Amesfoort; Martin Hermann; Yasin Ince; Maurice J Zwart; Agustina V Echague; Yan Chen; Baoyue Ding; Xuan Huang; Gert Storm; Michal Heger
Journal:  J Clin Transl Res       Date:  2019-05-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.